Ranbaxy Receives Approval to Market Ran-Rosuvastatin in Canada

MISSISSAUGA, Ontario, March 30, 2012 /CNW/ - Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RPCI has received approval from Health Canada to manufacture and market RAN™-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestor in Canada were $742.2 million ($CAD-IMS-CDH: January, 2012).

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI. He further added: "We are pleased to have gained approval for this molecule that will provide an affordable alternative to the brand. Such a generic formulation is anticipated to have a positive economic benefits to the healthcare system of Canada, as we all as to all Canadian patients that require Rosuvastatin therapy."

Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe.

CONTACTS: Charles M. Caprariello Paul Drake

Vice President, Corporate Communications President

Ranbaxy Inc. Ranbaxy Pharmaceuticals Canada, Inc.

(609) 720-5615 (905) 219-8820

SOURCE Ranbaxy Pharmaceuticals Canada Inc.

 

Posted: April 2012


View comments

Hide
(web4)